Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-D]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component.
1. 1.5 Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate salt having a water content in the range of 3.5-5.5%.
2. The 1.5 hydrate according to claim 1 , wherein characteristic peak values (2θ) in XRD diffractogram are 15, 18, 20, 21 and 23°.
3. A process for preparing the 1.5 hydrate according to claim 1 , characterized in that 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]-pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate salt is recrystallized from water, acetonitrile/water, ethanol/water, ethanol/hexane or ethyl acetate/hexane solvent.
4. The process according to claim 3 , wherein the recrystallizing solvent is water.
5. A pharmaceutical composition for inhibiting DPP-IV, which comprises the 1.5 hydrate according to claim 1 as the active component together with a pharmaceutically acceptable carrier.
6. The composition according to claim 5 , wherein it is used for the treatment of diabetes or obesity.